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Abstract The pleckstrin homology (PH) domain of the proto-
oncogenic serine/threonine protein kinase PKB/Akt can bind
phosphoinositides. A yeast-based two-hybrid system was em-
ployed which identified inosine-5Pmonophosphate dehydrogenase
(IMPDH) type II as specifically interacting with PKB/Akts PH
domain. IMPDH catalyzes the rate-limiting step of de novo
guanosine-triphosphate (GTP) biosynthesis. Using purified
fusion proteins, PKB/Akts PH domain and IMPDH associated
in vitro and this association moderately activated IMPDH.
Purified PKB/Akt also associated with IMPDH in vitro. We
could specifically pull-down PKB/Akt or IMPDH from mam-
malian cell lysates using glutathione-S-transferase (GST)^
IMPDH or GST^PH domain fusion proteins, respectively.
Additionally, PKB/Akt and IMPDH could be co-immunopreci-
pitated from COS cell lysates and active PKB/Akt could
phosphorylate IMPDH in vitro. These results implicate PKB/
Akt in the regulation of GTP biosynthesis through its interaction
with IMPDH, which is involved in providing the GTP pool used
by signal transducing G-proteins. ß 2000 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
The PKB/Akt subfamily of serine/threonine protein kinases,
consisting of K, L and Q isoforms [1^3], is closely related to the
cAMP-dependent protein kinase (PKA) and Ca2/phospholip-
id-dependent protein kinase (PKC) families in its kinase do-
main and contains an amino-terminal pleckstrin homology
(PH) domain [4]. The human PKB/AktK isoform is the pro-
tooncogenic form of v-akt, which encodes a complete PKB/
Akt with the addition of a truncated gag sequence at the
amino-terminus providing a myristoylation sequence [5].
Originally, the PH domain was identi¢ed as an internal
repeat, present at the amino- and carboxyl-termini of pleck-
strin, a 47 kDa protein which is the major PKC substrate in
activated platelets [6]. The superfamily of PH domain-contain-
ing molecules consists of over 90 members, including serine/
threonine protein kinases (PKB/Akt, Nrk, LARK, PKCW),
tyrosine protein kinases (Btk, Tec, Itk), GTPase regulators
(ras-GAP, ras-GRF, Vav, SOS, BCR), all known mammalian
phospholipase Cs, cytoskeletal proteins (L-spectrin, AFAP-
110, syntrophin), ‘adapter’ proteins (GRB-7, 3BP2) and ki-
nase substrates (pleckstrin, IRS-1) [4,7^12].
Structures have been solved for Bruton’s tyrosine kinase
(Btk), L-spectrin, pleckstrin, dynamin and phospholipase CN-
1 PH domains [13^17] and all are similarly folded. The pres-
ence of PH domains in many signaling and cytoskeletal pro-
teins implicates it in the mediation of signaling processes. In-
deed, the PH domain of the L-adrenergic receptor kinase
(LARK) appears partly responsible for its binding to the LQ-
subunits of the heterotrimeric G-proteins associated with the
L-adrenergic receptor [18,19]. While the PH domain of Btk
appears to mediate an interaction with PKC [20], more re-
cently, several PH domains have been shown to bind phos-
phoinositides (PIs) [21^25] and signaling pathways that are
initiated by PI 3-kinase appear to activate PKB/Akt. Previ-
ously, we have shown that the PH domain of PKB/Akt seems
to be pivotal in localizing it to the plasma membrane after
growth factor (insulin or IGF-1) stimulation [26,27], by virtue
of its ability to bind the PI 3-kinase product PtdIns(3,4,5,)P3
[25], where upon it becomes activated by at least one protein
kinase (USK/PKBK) [28,29]. Fully activated PKB/Akt is
phosphorylated on Thr308 and Ser473 [26,27] and is known
to phosphorylate and inactivate components of the apoptotic
machinery, BAD [30,31], Caspase9 [32] and FKHRL1 [33].
PKB/Akt then translocates to the nucleus [26,27] presumably
to phosphorylate other speci¢c protein targets.
Considering the importance of ascertaining the function of
PH domains and noting that we have previously shown PKB/
Akts PH domain speci¢cally binds PIs [25] while some other
PH domains appear to mediate protein^protein interactions
[18^20], we used the yeast two-hybrid system [34,35] to deter-
mine if PKB/Akts PH domain could function by forming
speci¢c associations with other proteins. In the present study
we have identi¢ed PKB/Akts PH domain as interacting with
inosine-5P monophosphate dehydrogenase (IMPDH) type II
in in vitro and in vivo binding assays. PKB/Akts PH domain
also appears to moderately stimulate IMPDH activity and
constitutively active PKB/Akt can phosphorylate IMPDH in
vitro. In conjunction with the known role of IMPDH in gua-
nosine-triphosphate (GTP) biosynthesis our ¢ndings suggest a
role for PKB/Akt in regulating the GTP pool used by signal
transducing G-proteins.
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2. Materials and methods
2.1. Bacterial and yeast strains
All yeast strains and plasmids for yeast two-hybrid experiments
were obtained from Clontech (Palo Alto, CA, USA) as components
of the Matchmaker Two-Hybrid System or from Dr. D. Nathans
(Howard Hughs Medical Institute, Baltimore, ML, USA). Yeast
strains SFY526 (MATa, ura3^52, his3^200, ade2^101, lys2^801,
trp1^901, leu2^3, 112, canr, gal4^542, gal80^538, URA3: :GAL1-
lacZ), HF7c (MATa, ura3^52, his3^200, lys2^801, ade2^101, trp1^
901, leu2^3, 112, gal4^542, gal80^538, LYS2: :GAL1-HIS3, URA3: :
(GAL4 17-mer)3-CYC1-lacZ) and PCY2 [36] (MATK, his3^200, ade2^
101, lys2^801, trp1^63, leu2^3, gal4^542, gal80^538, URA3: :GAL1-
lacZ) were used to assay for protein^protein interactions. The yeast
strain HF7c was used for library screening. Yeast techniques including
transformation were performed according to the instructions in the
Matchmaker Two-Hybrid System manual and as previously described
[37]. The bacterial strains XL1-blue and JM109 (Stratagene) were
employed in the cloning of plasmids and the production of gluta-
thione-S-transferase (GST) fusion proteins. The bacterial strains
JM109(DE3), BL21(DE3)pLysS and BL21(DE3)pLysE (Invitrogen)
were used for the production of (His)6-tagged proteins. General mo-
lecular biological techniques were performed as previously described
[38,39].
2.2. Plasmid construction
Yeast vector plasmids containing the GAL4 DNA binding domain
(amino acids 1^147, pGBT9) and the GAL4 activation domain (ami-
no acids 768^881, pGAD424) as well as the control plasmids pCL1
(full-length GAL4 gene), pVA3 (p53 gene), pTD1 (SV40 large T anti-
gen), and pLAM5P (human lamin C gene) were from Clontech. The
yeast vector pPC62, containing the GAL4 DNA binding domain, was
a gift from Dr. D. Nathans. The GST fusion vector pGEX-2T was a
gift from Dr. P. Matias (FMI). The baculovirus transfer vector
(pVL1392) and the (His)6-tag vector (pRSET-A) were from Invitro-
gen. pGBT-PH(1^127), pGBT-PH(1^150), pGBT-PH(1^47) and
pGBT-PH(47^127) contained in-frame fusions of amino acids 1^127,
1^150, 1^47, 47^127 of the human PKB/AktK PH domain, respec-
tively, with the GAL4 DNA binding domain. They were constructed
by subcloning polymerase chain reaction (PCR) fragments generated
with speci¢c oligonucleotides into the EcoRI^BamHI sites of pGBT9.
pGEX-PH131 contained an in-frame fusion of amino acids 1^131
of human PKB/AktK with GST. It was constructed by subcloning a
PCR fragment generated with speci¢c oligonucleotides into the Bam-
HI^EcoRI sites of pGEX-2T. pGBT-PH-Kin(1^411), pGBT-PH-Kin-
COOH(1^480), pGBT-Kin-COOH(147^480), pGBT-Kin(147^411)
and pGBT-COOH(411^480) contained in-frame fusions of amino
acids 1^411, 1^480, 147^480, 147^411 and 411^480 of human PKB/
AktK, respectively, with the GAL4 DNA binding domain. They were
constructed by subcloning the appropriate BamHI^EcoRI fragments
from corresponding pGEX constructs into the PstI^XbaI sites of
pPC62 using PstI^BamHI and EcoRI^XbaI adapters. The XhoI^
XbaI fragments from the resultant pPC62 plasmids were then isolated
and subcloned into the XhoI^EcoRI sites of pGBT9 using an XbaI^
EcoRI adapter. The plasmids pGAD-IMPDH(1^481), pGAD-
IMPDH(1^427), pGAD-IMPDH(1^325), pGAD-IMPDH(28^514),
pGAD-IMPDH(70^514), pGAD-IMPDH(1^40) and pGAD-
IMPDH(428^514) contained in-frame fusions of amino acids 1^481,
1^427, 1^325, 28^514, 70^514, 1^40 and 428^514 of human IMPDH
type II, respectively, with the GAL4 activation domain. They were
constructed by subcloning PCR fragments generated with speci¢c oli-
gonucleotides into the BamHI^SalI sites of pGAD424.
pGEX-IMPDH contained an in-frame fusion of the complete hu-
man IMPDH type II cDNA with GST. It was constructed by sub-
cloning the SmaI^XhoI fragment of IMPDH from pGADGH-
IMPDH into the SmaI site of pGEX-2T using a XhoI^SmaI adapter.
pVL1392-hPKB/AktK contained the EcoRI fragment from WI38x-
Akt71 [1] encompassing the full coding region of human PKB/AktK.
pRSET-PHQKKK [40] contains an in-frame fusion of amino acids 1^
116 of human PKB/AktK with an amino-terminal (His)6-tag, and the
addition of three lysines at the carboxyl terminus. It was constructed
by subcloning an NdeI^P£MI fragment from pRK-RAC [1] into the
BamHI^EcoRI sites of pRSET-A using BamHI^NdeI and P£MI^
EcoRI adapters. The eukaryotic expression constructs of hemaggluti-
nin (HA)-tagged PKB/AktK, wild-type (pCMV5-HA-PKB/Akt), ki-
nase inactive (pCMV5-HA-PKB/Akt-K197A) and constitutively ac-
tive (pCMV5-HA-PKB/Akt-T308D/S473D) forms have been
described previously [26]. All plasmid constructions were con¢rmed
by restriction fragment analysis and sequencing. Further details of
plasmid constructs are available upon request.
2.3. Library screening
The human HeLa S3 Matchmaker cDNA library was purchased
from Clontech. pGBT-PH127 was transformed into HF7c with and
without the control plasmids (pGAD424, pCL1 and pTD1). Colonies
from this transformation were tested for HIS3 and LacZ expression to
con¢rm that the PH domain alone does not activate transcription.
The HF7c yeast containing just pGBT-PH127 was then transformed
with enough of the HeLa S3 cDNA library inserted into the two-
hybrid activation vector pGADGH to produce 1.0U106 yeast Leu/
Trp transformants. Doubly transformed cells were plated onto
Leu3/Trp3/His3 plates and incubated at 30‡C for 8 days. Positive
colonies were picked, restreaked onto Leu3/Trp3/His3 plates and
assayed for LacZ activity by the ¢lter assay. Library clones that
were His and LacZ were then cured of the pGBT-PH127 plasmid
and tested again for His auxotrophy and LacZ activity. Cured clones
that were negative in both assays were then mated to PCY2 yeast
containing either pGBT9, pGBT-PH127, pGBT-KIN-CT, pLAM5P
or pTD1. Clones corresponding to the diploids which had became
positive for both His auxotrophy and LacZ activity only in the pres-
ence of pGBT-PH127 were designated as true positives and then se-
quenced.
2.4. In vitro binding studies
GST fusions produced from the plasmids pGEX-2T, pGEX-PH131
and pGEX-IMPDH were expressed in Escherichia coli XL-1 blue cells
by induction with 0.1 mM isopropyl L-D-thiogalactoside (IPTG) for
2 h at 24‡C. The fusion proteins were puri¢ed as previously described
[41] except that the cells were lysed in a French Press. Full-length
human PKB/AktK was expressed and puri¢ed from the baculovirus
system. Brie£y, a baculovirus was constructed by co-transfection of
Sf9 cells with pVL1392-RACK and wild-type baculovirus AcMNPV
DNA. The resultant recombinant virus was then puri¢ed by limiting
dilution and detected by dot-blot hybridization. The puri¢ed virus was
used to produce human PKB/AktK in Sf9 cells. The human PKB/
AktK was puri¢ed by sequential anion exchange, phenyl-Sepharose
and gel ¢ltration chromatography. The human PKB/AktK PH domain
(His)6-tagged fusion produced by Bl21(DE3)pLysS cells transformed
with pRSET-PHQKKK was expressed and puri¢ed as described [40].
Brie£y, cells were induced with 0.2 mM IPTG for 2 h at 24‡C before
harvesting. Cell pellets were lysed in a French Press and the soluble
PH domain was puri¢ed sequentially on Ni(II) a⁄nity, cation ex-
change and gel ¢ltration columns. Binding studies were performed
using GST fusions (2.5 Wg) coupled to glutathione-agarose beads in
binding bu¡er (20 mM phosphate bu¡er pH 7.2, 150 mM NaCl, 1%
Triton X-100, 5 mM DTT) containing 2.5 Wg of (His)6-tagged PH
domain or baculovirus produced human PKB/AktK in a total volume
of 100 Wl. The samples were incubated at 4‡C for 1^2 h with agitation
every 5 min. The beads were then washed three times with bu¡er (20
mM phosphate bu¡er pH 7.2, 150 mM NaCl) before being analyzed
by sodium dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) and stained with Coomassie blue R-250 or followed by West-
ern blot analysis using a human PKB/AktK-speci¢c antiserum [1]. The
secondary antibody was a horse radish peroxidase coupled anti-rabbit
antibody (Amersham) which was detected using the enhanced chem-
iluminescence (ECL) method (Amersham) by autoradiography.
2.5. In situ pull-down assay
MCF-7 cells were lysed in bu¡er (50 mM Tris^HCl pH 8.0, 120
mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM EGTA, 30 mM pNPP, 25
mM L-glycerol phosphate, 15 mM PPi, 25 mM NaF, 1 mM vanadate,
20 WM PAO, 1 mM benzamidine, 0.1 mM PMSF) using 12 strokes
of a Dounce homogenizer. Soluble protein from the supernatant of
lysates centrifuged at 14 000Ug for 15 min at 4‡C was added to GST,
GST^PH or GST^IMPDH protein (5 Wg) attached to glutathione-
agarose beads and incubated at 4‡C for 2 h with continuous agitation.
The beads were then washed four times with lysis bu¡er before
being analyzed by Western blotting as described above with the hu-
man PKB/AktK-speci¢c antiserum or an IMPDH-speci¢c antiserum
[42].
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2.6. In vivo binding assay
Monkey COS cells were transfected with the plasmids pCMV5-HA-
PKB/Akt (wild-type HA-tagged PKB/Akt), pCMV5-HA-PKB/Akt-
K197A (kinase inactive HA-tagged PKB/Akt) or pCMV5-HA-PKB/
Akt-T308D/S473D (constitutively active HA-tagged PKB/Akt) using
Lipofectamine 2000 (Gibco BRL) according to the manufacturers in-
structions. After 48 h the cells were harvested, lysed in bu¡er (see
Section 2.5) and immunoprecipitated with HA (BAbCo, Berkeley,
CA, USA) or IMPDH-speci¢c antibodies. The IMPDH-speci¢c anti-
body was generated against the peptide YSGELKFEKRTSSAQ-
VEGGVHSLHSYEKRLF. Immunoprecipitates were collected with
protein-G beads (Sigma) and washed three times with lysis bu¡er.
Immunoprecipitates were then analyzed by SDS^PAGE followed by
Western blotting using HA, IMPDH or a human PKB/AktK-speci¢c
antiserum [1]. The secondary antibody was a horse radish peroxidase
coupled anti-rabbit antibody (Amersham) which was detected using
the ECLplus method (Amersham) by autoradiography.
2.7. In vitro kinase assay
COS cells transfected with pCMV5-HA-PKB/Akt-K197A or
pCMV5-HA-PKB/Akt-T308D/S473D were lysed and immunoprecipi-
tated with HA-speci¢c antibodies (BAbCo) as described in Section
2.6. The immunoprecipitated HA-PKB/Akt-K197A or HA-PKB/
Akt-T308D/S473D protein was then used in kinase assays with puri-
¢ed GST or GST^IMPDH as substrate. Puri¢ed GST fusions were
prepared as described in Section 2.4. Kinase reaction conditions were
similar to those previously described [1] and were carried out in bu¡er
(50 mM Tris^HCl pH 7.5, 1 mM DTT, 10 mM MgCl2, 1 WM PKI, 3.3
WM [Q-32P]ATP) with 5 Wg of GST fusion and 20 Wl of immunopreci-
pitated PKB/Akt protein. Reactions were carried out at 30‡C for 30
min before analysis by SDS^PAGE, transfer to PVDF membrane
(Amersham) and quantitated on a phosphoimager 445-SI (Molecular
dynamics, Sunnyvale, CA, USA).
2.8. IMPDH enzyme assay
Assays for IMPDH activity were performed essentially as described
[43] monitoring the production of XMP by absorbance at 286 nm.
The IMPDH was produced as a GST fusion and puri¢ed on gluta-
thione-agarose beads and eluted as soluble protein with reduced glu-
tathione. IMPDH activity was tested in the presence of either soluble
GST (produced from pGEX-2T) or PH domain (produced from
pGEX-PH131) at a molar ratio of IMPDH to GST/PH domain of
1:5.
3. Results
To determine if PKB/Akts PH domain could interact with
other proteins we fused it to the GAL4 DNA binding domain
and screened a HeLa cDNA library fused to the GAL4 tran-
scriptional activation domain in the yeast reporter strain
HF7c. In our screen of 1.0U106 primary transformants we
Fig. 1. Interaction of the PKB/AktK with IMPDH type II in the yeast two-hybrid system. A: Co-transformants of Gal4 DNA binding con-
structs pGBT9 (GAL4-DB), pGBT-PH127 (PH(1^127)) pGBT-PHIV-VI (PH(47^127)), pGBT-PHI-III (PH(1^47)), pGBT-PH150 (PH(1^150)),
pGBT-PH-KIN (PH-Kin(1^411)), pGBT-PH-KIN-CT (PH-Kin-COOH(1^480)), pGBT-KIN (Kin(147^411)), pGBT-KIN-CT (Kin-COOH(147^
480)) and pGBT-CT (COOH(411^480)) with either pGAD424 (Gal4 AD), pGADGH-IMPDH (IMPDH), pVA3 (p53) or pLAM5P (hLAM-C)
in HF7c cells were selected on Leu3/Trp3 plates and then replated onto Leu3/Trp3/His3 plates to detect activation of the HIS3 reporter. Liq-
uid L-gal assays of the above co-transformants were also performed in SFY526 cells. Assays were performed in triplicate. B: Delineation of the
PKB/AktK PH domain binding region of IMPDH type II using the yeast two-hybrid system. Co-transformants of the Gal4 activation domain
constructs pGAD424 (GAL4-AD), pGADGH-IMPDH (IMPDH(1^514)), pGAD-IMPDH1^481 (IMPDH(1^481)), pGAD-IMPDH1^427
(IMPDH(1^427)), pGAD-IMPDH1^325 (IMPDH(1^325)), pGAD-IMPDH28^514 (IMPDH(28^514)), pGAD-IMPDH70^514 (IMPDH(70^
514)), pGAD-IMPDH1^40 (IMPDH(1^40)) and pGAD-IMPDH428^514 (IMPDH(428^514)) were selected and assayed as described in (A). See
Section 2 for plasmid construction details.
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identi¢ed 37 clones which showed speci¢c interaction with
PKB/Akts PH domain, by activation of the reporters for
His auxotrophy and LacZ activity (Fig. 1A). These clones
could be subdivided into six di¡erent cDNA classes, based
on the size of the cDNA insert. Upon sequencing all clones
where found to encode human IMPDH type II inclusive of
the initiator methionine through to the termination codon of
the previously cloned cDNA [42]. IMPDH catalyzes the rate-
limiting step of de novo GTP biosynthesis in the NAD-depen-
dent conversion of IMP to XMP [42,43].
The interaction we have identi¢ed requires a complete PH
domain as constructs containing either subdomains I^III
(amino acids 1^47) or subdomains IV^VI (amino acids 47^
127) alone did not show any interaction with IMPDH. The
lack of interaction with subdomains IV^VI is signi¢cant as
this region has previously been shown to interact weakly
with the LQ-subunits of heterotrimeric G-proteins [19]. This
interaction of IMPDH and PKB/Akts PH domain is, how-
ever, inhibited in the two-hybrid system with constructs con-
taining PKB/Akts kinase domain juxtaposed to PKB/Akts PH
domain as occurs in its natural context. These constructs were
expressed correctly in the yeast as they interacted with a con-
trol protein known to interact with the PKB/Akt carboxyl-
terminal region (results not presented). This inhibition of in-
teraction could be due to an intramolecular interaction of
PKB/Akts PH domain with itself or another region of PKB/
Akt. Inclusion of amino acids between the PH and kinase
domains (including the ¢rst four amino acids of the kinase
domain) didn’t inhibit the interaction. We also fused PKB/
Akts PH domain to the GAL4 activation domain to test if
it could interact with any of the human PKB/AktK GAL4
DNA binding constructs. We could detect no such interac-
tion, indicating that the PH domain doesn’t self associate or
form a complex with other regions of the PKB/Akt molecule
in this system (Fig. 1A). The inhibition of interaction, ob-
Fig. 2. Detection of IMPDH-PKB/Akt association in in vitro bind-
ing assays and in in situ pull-down assays from MCF-7 cell lysates.
A: Binding of a (His)6-tagged human PKB/AktK PH domain to
GST^IMPDH coated beads. GST or GST^IMPDH beads were in-
cubated with or without the (His)6-tagged PH domain as indicated.
After washing, the protein attached to the beads was analyzed by
Coomassie staining of an SDS^PAGE gel. B: Binding of baculovi-
rus produced human PKB/AktK to GST^IMPDH coated beads.
GST, GST^PH or GST^IMPDH beads were incubated with or
without the baculovirus produced human PKB/AktK as indicated.
After washing, the protein attached to the beads was analyzed by
SDS^PAGE followed by Western blotting using a human PKB/
AktK-speci¢c antiserum as described in Section 2. C: Association of
human PKB/AktK from MCF-7 cell extracts with GST^IMPDH
and not GST. GST or GST^IMPDH beads were incubated with or
without MCF-7 cell extracts as indicated. After washing, the protein
attached to the beads was analyzed by SDS^PAGE followed by
Western blotting using a human PKB/AktK-speci¢c antiserum as de-
scribed in Section 2. D: Association of human IMPDH from MCF-
7 cell extracts with GST^PH and not GST. GST or GST^PH beads
were incubated with or without MCF-7 cell extracts as indicated.
After washing, the protein attached to the beads was analyzed by
SDS^PAGE followed by Western blotting using an IMPDH-speci¢c
antiserum as described in Section 2.
Fig. 3. Detection of IMPDH-PKB/Akt association in vivo and
phosphorylation of IMPDH by PKB/Akt in vitro. A: Co-immuno-
precipitation of IMPDH and HA-tagged PKB/AktK, wild-type (HA-
PKB/Akt), kinase inactive (HA-PKB/Akt-K197A) and constitutively
active (HA-PKB/Akt-T308D/S473D) forms expressed in COS cells.
Cell lysates from cells expressing the various constructs indicated, or
moc-transfected, were immunoprecipitated (IP) with HA-speci¢c or
IMPDH-speci¢c antibodies. The immunoprecipitates were then ana-
lyzed by SDS^PAGE and Western blotting using HA-, IMPDH-, or
PKB/Akt-speci¢c antibodies as described in Section 2. B: Phosphor-
ylation of GST^IMPDH by constitutively active PKB/AktK and not
kinase inactive PKB/AktK. Kinase inactive (K197A) and constitu-
tively active (T380D/S473D) forms of HA-tagged PKB/Akt were im-
munoprecipitated from COS cell lysates and then added to puri¢ed
GST or GST^IMPDH with [Q-32P]ATP in a kinase bu¡er as de-
scribed in Section 2. Kinase reactions were then analyzed by SDS^
PAGE followed by transfer to PVDF membrane and the radioactiv-
ity was quantitated on a phosphoimager 445-SI (Molecular dynam-
ics, Sunnyvale, CA, USA).
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served above, in the yeast two-hybrid system would thus ap-
pear to be due to steric hindrance.
We constructed nested amino- and carboxyl-terminal dele-
tions of IMPDH to determine the region of the molecule
responsible for interaction with PKB/Akts PH domain (Fig.
1B). This indicated that an almost intact IMPDH molecule
was required for the interaction. The amino-terminal bound-
ary of the PH interaction domain was found to lie between
amino acids 28 and 70, while the carboxyl-terminal boundary
lies between amino acids 427 and 481.
To test if IMPDH could interact directly with PKB/Akts
PH domain we employed an in vitro binding assay system
using GST fusions (Fig. 2A). In this assay we see that the
(His)6-tagged PH domain can bind to the GST^IMPDH fu-
sion but not to GST alone. We also employed this assay
system to test if full-length baculovirus puri¢ed human
PKB/AktK could directly interact with IMPDH (Fig. 2B).
Here we see a speci¢c interaction of the full-length PKB/Akt
molecule with GST^IMPDH and not GST alone or the GST^
PH fusion. Also, when we used the GST^IMPDH in a pull-
down assay with MCF-7 cell extracts we see a speci¢c asso-
ciation of human PKB/AktK with the GST^IMPDH and not
with GST (Fig. 2C). We could also perform the converse
experiment, pulling down IMPDH from cell lysates using
the GST^PH domain fusion protein (Fig. 2D). Thus, we
have shown the existence of an association between human
PKB/AktK and human IMPDH type II in three heterologous
systems, yeast two-hybrid, in vitro puri¢ed protein interac-
tions and in situ pull-downs.
To test if PKB/Akt and IMPDH could interact in vivo we
expressed HA-tagged wild-type, kinase inactive (K197A) and
constitutively active (T308D/S743D) forms of PKB/Akt in
COS cells and then immunoprecipitated PKB/Akt with HA-
speci¢c antibodies or IMPDH with a speci¢c antiserum. The
results (Fig. 3A) show that the constitutively active form of
PKB/Akt (T308D/S743D) co-immunoprecipitated with
IMPDH. This occurred when we immunoprecipitated PKB/
Akt and probed for IMPDH and when we immunoprecipi-
tated IMPDH and probed for PKB/Akt. We next examined if
the constitutively active PKB/Akt immunoprecipitated from
COS cells could phosphorylate IMPDH (Fig. 3B). These re-
sults show that indeed the constitutively active PKB/Akt is
able to phosphorylate a GST fusion of IMPDH and not
GST alone.
We then assayed the e¡ect of this interaction on the activity
of IMPDH. The addition of soluble PH domain as a GST
fusion to IMPDH produced a moderate activation of the
enzyme compared to the addition of GST alone (Fig. 4).
4. Discussion
Recently we have learned much about the involvement of
PKB/Akt in PI3 kinase signaling pathways where PIs alter the
subcellular localization of PKB/Akt [25,26] and other kinases
(USK/PKBK) provide activating phosphorylations [28,29,44]
for PKB/Akt. Considering the importance of ascertaining the
full spectrum of molecules involved in the regulation of PKB/
Akt we used the yeast two-hybrid system [34,35] to determine
if PKB/Akts PH domain could function by forming speci¢c
interactions with other proteins. This method has found wide
application in demonstrating interactions between Bcl-2 and
R-Ras p23 [45], SOS1 and GRB2 [46], Ras and Raf [47,48],
and Raf and 14-3-3 [49]. In the present study the two-hybrid
system was able to demonstrate PKB/Akts PH domain as
interacting speci¢cally with an enzyme involved in the rate-
limiting step of de novo guanine biosynthesis, IMPDH [42]. It
also required an intact PH domain, and was not conferred by
the region (subdomains IV^VI plus a carboxyl-terminal exten-
sion) which has previously been shown to bind weakly to the
LQ-subunits of heterotrimeric G-proteins [19].
Interestingly, in the two-hybrid system we couldn’t detect
this interaction when full-length PKB/Akt was used instead of
just its PH domain. This could suggest that the PH domain
may be interacting with part of the PKB/Akt molecule itself
and thus masking its interaction with IMPDH. However,
when we tested the ability of PKB/Akts PH domain (amino
acids 1^127) to interact with the various PKB/Akt domain
constructs in the two-hybrid system we could ¢nd no support
for such a hypothesis. Recent evidence, however, suggests that
there are intramolecular interactions within PKB/Akt [50,51],
demonstrated with a PKB/Akt PH domain-containing con-
struct (amino acids 1^147). However, Datta et al. [51] dem-
onstrate a lack of interaction between PKB/Akt and just the
PH domain (amino acids 1^109), suggesting the V40 amino
acid carboxyl terminal extension was in part responsible for
the binding. Our PH domain constructs contained only half of
this extended region, which could explain our inability to ¢nd
any intramolecular interaction. Alternatively, the inability to
observe an interaction of IMPDH type II with full-length
PKB/Akt in the yeast two-hybrid system could be due to
steric hindrance. The constructs with a domain £anking
both ends of the PH domain failed to interact with IMPDH,
while those £anked at only one end did. Another possible
explanation would be that there is a mode of regulation of
the interaction, by an auxiliary molecule or post-translational
modi¢cation, which is in the non-permissive state in the two-
hybrid system when the full-length PKB/Akt molecule is used.
We were able to reproduce this interaction in an in vitro
binding system using a GST fusion of IMPDH and a (His)6-
Fig. 4. E¡ect of the PKB/Akt PH domain on IMPDH activity in vi-
tro. IMPDH expressed and puri¢ed as a GST fusion was incubated
with a ¢ve-fold molar excess of either GST^PH domain fusion pro-
tein or GST alone under IMPDH assay conditions as described in
Section 2. The production of XMP was monitored by measuring
the change in optical density at 286 nm. Each time point was as-
sayed in triplicate and error bars represent a 99% con¢dence inter-
val.
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tagged PH domain. This corroboration in a heterologous sys-
tem lends weight in support of the interaction being biolog-
ically signi¢cant. This in vitro interaction also appeared to
produce a moderate activation of IMPDH. Due to the lack
of detectable interaction in the two-hybrid system between
full-length PKB/Akt and IMPDH we checked to see if we
could detect any such interaction in our in vitro binding sys-
tem. Indeed, we could show that a baculovirus produced hu-
man PKB/AktK could interact with IMPDH, again support-
ing a signi¢cance of the observed interaction. We could also
show that this interaction occurs using an in situ pull-down
assay with GST fusions and cell lysates from MCF-7 cells.
Further, we have demonstrated an in vivo association of
IMPDH and PKB/Akt by co-immunoprecipitation from
COS cells expressing a constitutively active form of PKB/
Akt. Finally, we were able to show that this constitutively
active PKB/Akt could phosphorylate IMPDH in vitro. The
above results thus support the view that this novel interaction
between human PKB/AktK and human IMPDH type II is of
signi¢cance and is promoted by PKB/Akts PH domain.
In our delineation of the region of IMPDH responsible for
binding to PKB/Akts PH domain we found we could only
delete small regions of the amino- and carboxyl-termini while
retaining interaction; producing a core protein of some 453
amino acids being required for the binding. This suggests that
the PH domain binding component of IMPDH is composed
of disperse elements distributed widely along its primary se-
quence. These elements may, however, be clustered into a
spatially small region in the three-dimensional structure of
IMPDH. This contrasts with the binding elements of the
SH2 [52] and SH3 [53] domains, which are composed of short
peptides of 10^20 amino acids, tyrosine phosphorylated in the
case of SH2 and proline rich in the case of SH3. The crystal
structure of human IMPDH type II has recently been solved
[54] and shows the presence of a catalytic domain (amino
acids 1^113 and 232^514) with an internal £anking domain
(amino acids 113^232). It is conceivable that the £anking do-
main could be the region responsible for binding the PKB/Akt
PH domain. Small truncations at either end of the IMPDH
molecule would a¡ect the catalytic core and may prevent the
correct folding of the rest of the molecule including the inter-
nal £anking domain. This scenario would be consistent with
our observations.
IMPDH is a highly conserved enzyme (41% amino acid
identity between bacterial and mammalian sequences) in-
volved in the rate-limiting step of guanine biosynthesis. In
mammals there are two isoforms (type I and type II) 84%
identical, which are di¡erentially expressed [55]. Type I is
constitutively expressed at low levels while the type II protein
is up-regulated during cellular proliferation [56]. IMPDH ac-
tivity levels are also elevated during rapid proliferation in
many cells [57].
By measuring the metabolic £uxes, the proliferative index of
intact cancer cells has been shown to be linked with the pref-
erential channeling of IMP into guanylate biosynthesis [55].
Inhibition of cellular IMPDH activity results in an abrupt
cessation of DNA synthesis and a cell-cycle block at the
G1^S interface leading to apoptosis [58]. The speci¢c inhibi-
tion of IMPDH by tiazofurin and the subsequent decline in
the GTP pool, results in the down-regulation of the G-protein
ras [59], which is involved in many signal transduction path-
ways leading to cellular proliferation [60]. These results impli-
cate IMPDH as a central player in regulating normal cellular
proliferation and the neoplastic state.
Interestingly, p53 has been implicated in regulating IMPDH
activity levels [61]. Here, a moderate over-expression of p53
(3^6-fold) induces a profound growth arrest which is rescued
by purine nucleotide precursors. Indeed, the p53 over-expres-
sion induces a speci¢c block in IMP to XMP conversion, and
a diminished activity level of IMPDH. The p53 block doesn’t
a¡ect the rate of RNA synthesis, nor is the phenotype rescued
by deoxynucleotides indicating that a lack of precursors for
DNA synthesis is also not the cause of the block. It would
seem most likely that this e¡ect is mediated through a down-
regulation of the GTP pool required by G-proteins such as
ras.
The above observations suggest that IMPDH type II is
primarily involved in producing XMP which is then channeled
into the GTP pool and is crucial for the regulation of G-
proteins involved in signal transduction such as ras. It may
be that the type I enzyme provides a basal level of XMP that
is channeled into the GTP/dGTP pools required for RNA and
DNA synthesis. Changes in IMPDH type II activity would
alter the GTP/GDP ratio by speci¢cally altering the GTP
component which could greatly a¡ect ras signaling pathways
as ras is sensitive to small changes in the GTP/GDP ratio [62].
Thus, the ¢ndings presented here, of an interaction between
IMPDH type II and the protooncogenic serine/threonine pro-
tein kinase PKB/Akt, could have signi¢cance in the regulation
of ras and other G-protein linked signal transduction path-
ways. This interaction could also be important for regulation
of the apoptotic machinery as both molecules appear to be
involved with this mechanism of cell death.
With our ¢nding that a constitutively active form of PKB/
Akt could phosphorylate IMPDH in vitro, the potential for
PKB/Akt to regulate IMPDH in vivo through phosphoryla-
tion must be considered. Interestingly, it has recently been
shown [63] that in the pyrimidine biosynthesis pathway of
mammalian cells there is a cell-cycle regulation of thymidine
kinase by phosphorylation as well as by transcription and
translation [64]. Our ¢ndings are provocative of suggesting a
role of phosphorylation in the regulation of the purine bio-
synthetic pathway. In conjunction with the known role of
IMPDH in GTP biosynthesis our ¢ndings suggest a role for
PKB/Akt in regulating the GTP pool which is required by
signal transducing G-proteins. It is provocative that activation
of the PKB/Akt pathway promotes cyclin D1 translation al-
lowing G1^S phase progression [65], and that IMPDH type II
activity is required at the G1^S interface. Thus, the interplay
between PKB/Akt and IMPDH reported here could suggest
that PKB/Akt activation leads to IMPDH type II activation
which in turn prepares the cell for entry into S phase.
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